HU9503321D0 - Carbazole derivatives with 17,20-lyase-inhibiting activity - Google Patents

Carbazole derivatives with 17,20-lyase-inhibiting activity

Info

Publication number
HU9503321D0
HU9503321D0 HU9503321A HU9503321A HU9503321D0 HU 9503321 D0 HU9503321 D0 HU 9503321D0 HU 9503321 A HU9503321 A HU 9503321A HU 9503321 A HU9503321 A HU 9503321A HU 9503321 D0 HU9503321 D0 HU 9503321D0
Authority
HU
Hungary
Prior art keywords
lyase
inhibiting activity
carbazole derivatives
carbazole
derivatives
Prior art date
Application number
HU9503321A
Other languages
Hungarian (hu)
Other versions
HUT73790A (en
Inventor
Peter Clive Cherry
John Derek Cocker
Andrew Searle
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HU9503321D0 publication Critical patent/HU9503321D0/en
Publication of HUT73790A publication Critical patent/HUT73790A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
HU9503321A 1993-05-21 1994-05-19 Carbazole derivatives, pharmaceutical compositions containing them and process for proucing them HUT73790A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939310635A GB9310635D0 (en) 1993-05-21 1993-05-21 Chemical compounds

Publications (2)

Publication Number Publication Date
HU9503321D0 true HU9503321D0 (en) 1996-01-29
HUT73790A HUT73790A (en) 1996-09-30

Family

ID=10736007

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9503321A HUT73790A (en) 1993-05-21 1994-05-19 Carbazole derivatives, pharmaceutical compositions containing them and process for proucing them

Country Status (19)

Country Link
EP (1) EP0699196A1 (en)
JP (1) JPH08510455A (en)
CN (1) CN1126473A (en)
AU (1) AU6928794A (en)
BG (1) BG100154A (en)
CA (1) CA2162921A1 (en)
CZ (1) CZ305195A3 (en)
FI (1) FI955587A0 (en)
GB (1) GB9310635D0 (en)
HU (1) HUT73790A (en)
IL (1) IL109703A0 (en)
NO (1) NO954681D0 (en)
OA (1) OA10195A (en)
PE (1) PE31195A1 (en)
PL (1) PL311702A1 (en)
SK (1) SK142495A3 (en)
TW (1) TW279866B (en)
WO (1) WO1994027989A1 (en)
ZA (1) ZA943494B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960704852A (en) * 1993-09-30 1996-10-09 오노다 마사요시 Azole derivatives and pharmaceutical compositions thereof
WO1996014090A1 (en) * 1994-11-07 1996-05-17 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
EP0820989A4 (en) * 1995-03-01 1998-05-06 Yamanouchi Pharma Co Ltd Imidazole derivatives and medicinal composition thereof
US6420375B1 (en) * 1997-02-21 2002-07-16 Takeda Chemical Industries, Ltd. Fused ring compounds, process for producing the same and use thereof
DE60119963T2 (en) 2000-11-17 2006-10-05 Takeda Pharmaceutical Co. Ltd. IMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND THEIR USE
DE60144246D1 (en) 2000-11-20 2011-04-28 Takeda Pharmaceutical IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
DE60139639D1 (en) 2000-12-08 2009-10-01 Takeda Pharmaceutical SUBSTITUTED THIAZONE DERIVATIVES WITH 3-PYRIDYL GROUPS, PROCESS FOR THEIR PREPARATION AND THEIR USE
CA2612723A1 (en) * 2005-06-24 2007-01-04 Eli Lilly And Company Tetrahydrocarbazole derivatives useful as androgen receptor modulators
GB0525323D0 (en) * 2005-12-13 2006-01-18 Sterix Ltd Compound
US8093279B2 (en) 2005-12-13 2012-01-10 Gillian Reed, legal representative Compound
CN100586932C (en) * 2007-01-26 2010-02-03 中国医学科学院医药生物技术研究所 Antitumor compound and its preparation process
DK2445903T3 (en) 2009-06-26 2014-06-23 Novartis Ag 1,3-Disubstituted imidazolidin-2-one derivatives as CYP17 inhibitors
AU2011212813B2 (en) * 2010-02-04 2014-10-23 Radius Health, Inc. Selective androgen receptor modulators
US20130053448A1 (en) 2010-05-12 2013-02-28 Louis O'Dea Therapeutic Regimens
WO2012018948A2 (en) 2010-08-04 2012-02-09 Pellficure Pharmaceuticals, Inc. Novel treatment of prostate carcinoma
WO2012035078A1 (en) 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
ES2656218T3 (en) 2011-04-28 2018-02-26 Novartis Ag 17 alpha-hydroxylase / C17,20-lyase inhibitors
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
AU2014241816B9 (en) 2013-03-14 2019-02-14 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
SI3122426T1 (en) 2014-03-28 2023-04-28 Duke University Treating breast cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
WO2016040896A1 (en) 2014-09-12 2016-03-17 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
WO2017223115A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
CA3044812A1 (en) 2016-10-24 2018-05-03 Pellficure Pharmaceuticals Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1,4-dione
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS229934B2 (en) * 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
GB8518743D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds

Also Published As

Publication number Publication date
AU6928794A (en) 1994-12-20
BG100154A (en) 1996-07-31
TW279866B (en) 1996-07-01
HUT73790A (en) 1996-09-30
IL109703A0 (en) 1994-08-26
FI955587A (en) 1995-11-20
PE31195A1 (en) 1995-10-18
ZA943494B (en) 1995-01-23
WO1994027989A1 (en) 1994-12-08
EP0699196A1 (en) 1996-03-06
NO954681L (en) 1995-11-20
SK142495A3 (en) 1996-06-05
FI955587A0 (en) 1995-11-20
CN1126473A (en) 1996-07-10
PL311702A1 (en) 1996-03-04
CZ305195A3 (en) 1996-06-12
GB9310635D0 (en) 1993-07-07
JPH08510455A (en) 1996-11-05
NO954681D0 (en) 1995-11-20
CA2162921A1 (en) 1994-12-08
OA10195A (en) 1996-12-18

Similar Documents

Publication Publication Date Title
HU9503321D0 (en) Carbazole derivatives with 17,20-lyase-inhibiting activity
GR3029455T3 (en) 3-Aryl-4-hydroxy-3-dihydrofuranone derivatives.
DE59403259D1 (en) Tetraaroxyperylen-3,4,9,10-tetracarbonsäurepolyimide
ZA934603B (en) thiazolylvinylphenyl derivatives.
AP9400613A0 (en) 2,6-diaminopurine derivatives
ZA942571B (en) 1,5 benzodiazepine derivatives
ZA941137B (en) Substitutet azolone derivatives.
AP9400657A0 (en) 1,5 benzodiazepine derivatives
EP0710107A4 (en) N,n,n-trimethylsphingosine derivatives
ZA946569B (en) 1,5-Diphenyl-3-pyrazolylalkyl-N-hydroxydithiocarbamates
HU9400745D0 (en) 2,4-diamino-3-hydroxy-carboxylic acid derivatives
HU9301651D0 (en) Pyridyl-1,2,5-oxadiazole-carbonamide-2-oxide derivatives
HU9302748D0 (en) 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz[c,d]indole derivatives
HU908313D0 (en) New 15-nitro-2betha, 3betha-dihydro- and 15-nitro-2betha, 3 betha,6,7-tetrahydro-tabersonine derivatives
PH30825A (en) Benzylamine derivatives.
HU9402534D0 (en) New naphtoxazine derivatives
HK1002589A1 (en) 2,3-Dihydrobenzofuran derivatives
ZA936048B (en) Novel 3-oxadiazolyl-1,6-napthyridine derivatives
ZA925184B (en) 3,4-dehydropiperidine derivatives
HU9402902D0 (en) 1,2-dihydro-2-oxo-3-methyl-sulfonyl-aminomethyl-pyridine derivatives
ZA948311B (en) 1,2-dihydro-2-oxo-pyridines
IL110556A0 (en) 7 alpha-amino-1, 1-dioxocephem l- valylamides
ZA941763B (en) Carpaine derivatives.
HU9501251D0 (en) 17,20-epoxy-20-substituted-pregnane derivatives
EP0683787A1 (en) 4'-o-sulfonyl-anthracycline derivatives.

Legal Events

Date Code Title Description
DFC4 Cancellation of temporary protection due to refusal